Short-Term Debt to Equity Ratio: Cassava Sciences, Inc. (SAVA)
Cassava Sciences, Inc. (SAVA) specializes in developing Alzheimer's disease therapies, where high business scalability is driven by patents and low production costs. Historical price action shows that this metric stands at 0.00. Massive R&D investments and strict FDA oversight create significant barriers to entry for new players. Meanwhile, the company retains key scientists through generous stock options, despite recruitment challenges.
Metric breakdowns and analytics for cassavasciences.com (SAVA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Cassava Sciences, Inc.|SAVA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Cassava Sciences|SAVA - Company Aggregate Debts|Debt to Book Capitalization Ratio Cassava Sciences Inc|SAVA - Long-Term Debt Volume|Company Short-Term Debt Cassava Sciences|Quick Ratio cassavasciences.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:SAVA Cassava
Assessing the credit risks of Cassava Sciences, Inc. (SAVA) requires an analysis of the ratio of short-term liabilities to equity, where a sharp increase in the short-term debt-to-equity ratio signals an impending cash crunch. For a biotech company facing legal pressure and seeking acquisition by a pharma behemoth, this indicator measures the ability to maintain operations without emergency refinancing amid limited organic viability.
Main competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Biohaven Ltd (BHVN)|Short-Term Debt to Equity Amylyx AMLX|Short-Term Debt to Capital Coefficient Trevi Corp (TRVI)|PRAX - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient anavex.com AVXL|CBLL: Short-Term Debt to Capital|Prothena Biosciences (PRTA) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio ALEC|Short-Term Debt to Equity ANNX|Short-Term Debt to Capital OMER|Short-Term Debt to Capital neurogene.com (NGNE)|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Scilex Holding Company, Inc. SCLX|TVGN: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alpha Cognition Inc.|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|Inhibikase Therapeutics Inc (IKT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital ASRT|COYA - Current Liabilities to Capital|Short-Term Debt to Equity Vistagen VTGN|OVID: Short-Term Debt to Capital Ratio|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|CervoMed, Inc. (CRVO) - Short-Term Debt to Equity Ratio|ATHE: Short-Term Debt to Capital|Current Liabilities to Capital Clene (CLNN)|Short-Term Debt to Equity PepGen Inc|jupiterneurosciences.com (JUNS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|ANVS (Annovis Bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|KLTO - Short-Term Debt to Equity|NRSN (NeuroSense Therapeutics) - Short-Term Debt to Capital Ratio|RVPH: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio MetaVia|Short-Term Debt to Equity Ratio NRXS|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Athira Pharma Inc ATHA|ADXN: Short-Term Debt to Equity Ratio|ALZN: Short-Term Debt to Equity|CYCN: Short-Term Debt to Capital|Protagenic Therapeutics, Inc. (PTIX) - Short-Term Debt to Capital|Short-Term Debt to Equity Pasithea Therapeutics Corp|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital chromocell.com CHRO|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Capital Marinus Pharma (MRNS)|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio neurobopharma.com (NRBO)|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Short-Term Debt to Equity Trevena, Inc TRVN|Short-Term Debt to Capital Coefficient Vigil Neuroscience Inc. (VIGL)|WENA - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient cerevel.com CERE